TheStreet home
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTCRYPTOMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTERTECHNOLOGY
Search

Robert Wasserman

Robert Wasserman

Articles From This Author

Allergan: Cramer's Top Takeaways
INVESTING

5 ways allergan can keep up momentum

5 Stocks Hedge Funds Hate for 2016
STOCKS

Skin in the game: This dermatology market stock is a good M&A bet

ICU Medical (ICUI) Stock Closed Higher on $1 Billion Pfizer Deal
OPINION

How to invest in your favorite MD

Would You Meet This CEO for a 6:30 A.M. Interview?
STOCKS

Rebound may be in store for beaten-down shares of TherapeuticsMD

Immunotherapy Stocks Power Higher on Celgene-Juno Deal
STOCKS

Momenta, coherus biosciences are both good options in the biosimilar space

5 Best-Positioned Biotech Stocks on Brexit Volatility
OPINION

Changes at the top for endo could benefit its smaller partners

Applied Genetic Technologies Is an Attractive Acquisition Target for Allergan or Biogen
STOCKS

Applied genetic technologies is an attractive acquisition target for allergan or biogen

Flexion's Latest FDA Approval Reignites Takeover Chatter
STOCKS

2 big companies and 1 small one to target in the pharma/biotech space

FDA deals blow to Endo over Opana ER Pain Med
STOCKS

ANI Pharmaceuticals' varied offerings, strategic acquisitions make it a good play for investors

WebMD Puts Itself Up for Sale
STOCKS

This little-known orthopedic-device stock is delivering huge returns

Changing Landscape for Generic-Drug Makers Creates Opportunities
INVESTING

Changing landscape for generic-drug makers creates opportunities

Opko Health, FireEye, KBR: 'Mad Money' Lightning Round
OPINION

Opko Health's many acquisitions add up to varied product offerings and potential growth

Valeant Acquires Eyegate Licensing Rights
OPINION

13 companies to watch from MIT's smart 50 list, including 4 buys

NxStage Medical Acquired by Fresenius for $2 Billion
OPINION

NeoGenomics deal with GE's Clarient 6 months later: boom or bust?

Opko Health, FireEye, KBR: 'Mad Money' Lightning Round
OPINION

Opko is a buying opportunity after FDA's approval of kidney drug